文献速递肺结节与肺癌

治疗等待时间对荷兰晚期非小细胞肺癌患者生存的影响:全国性观察性队列研究

Impact of time-to-treatment on survival for advanced non-small cell lung cancer patients in the Netherlands: a nationwide observational cohort study.
PubMed 文献 · Thorax · 2022-04-21

结果显示,III期仅放疗或系统治疗、IV期化疗和/或免疫治疗患者中,较长等待时间与死亡风险降低相关,但III期放化疗和IV期靶向治疗无显著关联。结论认为无证据表明更早开始治疗可改善晚期NSCLC结局。

要点

  • III期仅放疗患者等待>21天死亡风险降低(aHR 0.59)。
  • IV期化疗和/或免疫治疗等待>21天死亡风险降低(aHR 0.81)。
  • III期放化疗和IV期靶向治疗中等待时间与生存无显著关联。

核心结论

  • 研究未发现更早开始治疗可改善晚期NSCLC患者生存的证据。
  • 治疗紧迫性的获益可能受未测量的人口学和肿瘤特征及临床紧迫性混杂。

研究设计与样本

  • 采用Cox比例风险回归分析生存与治疗等待时间的关联,并调整诊断操作和治疗类型等多变量。
  • 采用多水平 logistic 回归识别与延迟相关的因素。

主要发现

  • III期仅接受放疗患者等待>21天与死亡风险降低相关(aHR 0.59,95%CI 0.48-0.73)。
  • III期接受任何类型系统治疗患者等待>49天与死亡风险降低相关(aHR 0.72,95%CI 0.56-0.91)。
  • IV期接受化疗和/或免疫治疗患者等待>21天与死亡风险降低相关(aHR 0.81,95%CI 0.73-0.88)。
  • III期接受放化疗和IV期接受靶向治疗的患者中未发现显著关联。
  • 更复杂的诊断操作常导致治疗延迟。

临床怎么用

  • 临床应认识到在晚期NSCLC中,治疗等待时间与生存的关联因治疗类型和分期而异。
  • 对于III期仅放疗、III期系统治疗和IV期化疗和/或免疫治疗患者,不应因担心等待时间而过度缩短必要诊断流程。
  • 需持续评估治疗等待时间的影响,尤其随着治疗策略演变。

局限性

  • 回顾性观察性设计,可能存在未测量混杂因素。
  • 治疗紧迫性的获益可能受临床紧迫性混杂影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The assumption that more rapid treatment improves survival of advanced non-small cell lung cancer (NSCLC) has not yet been proven. We studied the relation between time-to-treatment and survival in advanced stage NSCLC patients in a large multicentric nationwide retrospective cohort. Additionally, we identified factors associated with delay. METHOD: We selected 10 306 patients, diagnosed and treated between 2014 and 2019 for clinical stage III and IV NSCLC, from the Netherlands Cancer Registry that includes nationwide data from 109 Dutch hospitals. Associations between survival and time-to-treatment were tested with Cox proportional hazard regression analyses. Time-to-treatment was adjusted for multiple covariates including diagnostic procedures and type of therapy. Factors associated with delay were identified by multilevel logistic regression. RESULTS: Risk of death significantly decreased with longer time-to-treatment for stage III patients receiving only radiotherapy (adjusted HR, aHR >21 days: 0.59 (95% CI 0.48 to 0.73)) or any type of systemic therapy (aHR >49 days: 0.72 (95% CI 0.56 to 0.91)) and stage IV patients receiving chemotherapy and/or immunotherapy (aHR >21 days: 0.81 (95% CI 0.73 to 0.88)). No significant association was found for stage III patients treated with chemoradiotherapy and stage IV patients treated with targeted therapy. More complex diagnostic procedures often delay treatment. CONCLUSION: Although in general it is important to start treatment as early as possible, our study finds no evidence that a more rapid start of treatment improves outcomes in advanced stage NSCLC patients. The benefit of urgent treatment is probably confounded by unmeasured patient and tumour characteristics and, clinical urgency dictating timelines of treatment. Time-to-treatment and its impact should be continuously evaluated as therapeutic strategies continue to evolve and improve.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Klarenbeek SE, Aarts MJ, van den Heuvel MM, et al. Impact of time-to-treatment on survival for advanced non-small cell lung cancer patients in the Netherlands: a nationwide observational cohort study. Thorax. 2022. PMID: 35450944. doi:10.1136/thoraxjnl-2021-218059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。